Teva and Medicis settle over Solodyn
Israel-headquartered Teva Pharmaceutical Industries and US firm Medicis Pharmaceutical have agreed to terminate all legal disputes between them relating to Solodyn (minocycline HCl, USP) extended-release tablets. Under an agreement entered into between the parties, Teva has confirmed that Medicis patents relating to Solodyn are valid and enforceable, and cover its activities relating to its generic product under Abbreviated New Drug Application number 65-485. As part of the settlement, Teva has agreed to immediately stop all further shipments of generic versions of the drug. Medicis has agreed to release Teva from liability arising from any prior sales of its copy, which were not authorized by Medicis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze